Aerosolized polymerized type I collagen reduces airway inflammation and remodelling in a guinea pig model of allergic asthma.
Collagen-polyvinylpyrrolidone (Collagen-PVP) has been demonstrated to elicit immunomodulatory properties in different chronic inflammatory diseases. Nevertheless, its effects on asthma are still unknown. We have evaluated whether collagen-PVP could modulate airway inflammation and remodelling in a guinea pig model of allergic asthma. Sensitized guinea pigs were challenged with the allergen (ovalbumin) six times (at 10-day intervals). From the third challenge on, animals were treated every 5 days with saline aerosols containing 0.16, 0.33, or 0.66 mg/ml of collagen-PVP (n = 5, respectively). Some guinea pigs, sensitized and challenged with saline as well as treated with 0 or 0.66 mg/ml collagen-PVP, were included in the study as control (n = 7) and sham groups (n = 5), respectively. From the first challenge on, ovalbumin induced a transient airway obstruction, measured by barometric plethysmography, which was not modified by collagen-PVP treatments. After the last allergen challenge, guinea pigs were anesthetized to obtain bronchoalveolar lavage (BAL) and the left lung caudal lobe. As expected, BAL cell count from allergen-challenged guinea pigs showed abundant neutrophils and eosinophils, as well as numerous tumor necrosis factor (TNF)-alpha-expressing granulocytes and macrophages in airway wall (determined by immunohistochemical assay). Neutrophilia and TNF-alpha-expressing leukocytes, from collagen-PVP treated animals, diminished from 0.16 mg/ml, and eosinophilia from 0.66 mg/ml of collagen-PVP doses. Histological changes induced by allergen challenges include thickening of connective tissue below airway epithelium and vascular wall widening of airway adjacent vessels; these changes were reduced by collagen-PVP treatment. Collagen-PVP seems to have anti-inflammatory and antifibrotic properties in this guinea pig asthma model.
Moreno-Alvarez
Paola
P
Departamento de Biología Celular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Insurgentes Sur 3700, CP 04510 Mexico, DF, Mexico.
Sánchez-Guerrero
Edgar
E
Martínez-Cordero
Erasmo
E
Hernández-Pando
Rogelio
R
Campos
María G
MG
Cetina
Lucely
L
Bazán-Perkins
Blanca
B
D000280:Administration, Inhalation; D000336:Aerosols; D056151:Airway Remodeling / Q000187:drug effects*; D000485:Allergens; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D003094:Collagen / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004804:Eosinophils / Q000187:drug effects / Q000276:immunology; D006098:Granulocytes / Q000187:drug effects / Q000276:immunology; D006168:Guinea Pigs; D007150:Immunohistochemistry; D016676:Macrophages, Alveolar / Q000187:drug effects / Q000276:immunology; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology; D010047:Ovalbumin; D010991:Plethysmography; D011014:Pneumonia / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D011205:Povidone / Q000008:administration & dosage*; D011658:Pulmonary Fibrosis / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000336:Aerosols; D000485:Allergens; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D014409:Tumor Necrosis Factor-alpha; C120488:collagen-PVP; D010047:Ovalbumin; D003094:Collagen; D011205:Povidone